Characterization of kinin receptors in human cultured detrusor smooth muscle cells.
OBJECTIVE
Kinins have an important role in inflammatory cystitis and in animal pathophysiological models, by acting on epithelium, fibroblasts, sensory innervation and smooth muscle. The aim of this study was to characterize the receptors responsible for direct motor responses induced by kinins on human detrusor.


METHODS
Human detrusor cells from biopsies were isolated and maintained in culture. B(1) and B(2) kinin receptors were characterized by means of radioligand and functional experiments (PI accumulation and PGE(2) release).


RESULTS
[(3)H]-[desArg(9)]-Lys-BK and [(3)H]-BK saturation studies indicated receptor density (B(max)) and K (d) values of 19 or 113 fmol mg(-1), and 0.16 or 0.11 nM for the B(1) or B(2) receptors, respectively. Inhibition binding studies indicated the selectivity of the B(1) receptor antagonist [desArg(9)Leu(8)]-Lys-BK and of the B(2) receptor antagonists Icatibant and MEN16132. [DesArg(9)]-Lys-BK and BK induced PI accumulation with an EC(50) of 1.6 and 1.4 nM and different maximal responses (E(max) of [desArg(9)]-Lys-BK was 10% of BK). BK also induced prostaglandin E(2) release (EC(50) 2.3 nM), whereas no response was detected with the B(1) receptor agonist. The incubation of detrusor smooth muscle cells with interleukin 1beta (IL-1beta) or tumour necrosis factor-alpha (TNF-alpha) (10 ng ml(-1)) induced a time-dependent increase in radioligand-specific binding, which was greater for the B(1) than for the B(2) receptor.


CONCLUSIONS
Human detrusor smooth muscle cells in culture retain kinin receptors, and represent a suitable model to investigate the mechanisms and changes that occur under chronic inflammatory conditions.
Bellucci
F
F
Pharmacology Department, Menarini Ricerche S.p.A., Florence, Italy.
Cucchi
P
P
Santicioli
P
P
Lazzeri
M
M
Turini
D
D
Meini
S
S
D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D065169:Bradykinin B1 Receptor Antagonists; D002478:Cells, Cultured; D015232:Dinoprostone / Q000096:biosynthesis; D006801:Humans; D007295:Inositol Phosphates / Q000096:biosynthesis; D053583:Interleukin-1beta / Q000494:pharmacology; D007609:Kallidin / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009130:Muscle, Smooth / Q000166:cytology / Q000378:metabolism*; D009952:Ornithine / Q000031:analogs & derivatives / Q000494:pharmacology; D011869:Radioligand Assay; D043783:Receptor, Bradykinin B1 / Q000819:agonists / Q000378:metabolism / Q000502:physiology*; D013449:Sulfonamides / Q000494:pharmacology; D016211:Transforming Growth Factor alpha / Q000494:pharmacology; D001743:Urinary Bladder / Q000166:cytology / Q000378:metabolism*
C506838:(4-amino-5-(4-(4-(2,4-dichloro-3-(2,4-dimethyl-8-quinolyloxymethyl)phenylsulfonamido)tetrahydro-2H-4-pyranoylcarbonyl)piperazino)-5-oxopentyl)(trimethyl)ammonium; D065169:Bradykinin B1 Receptor Antagonists; D007295:Inositol Phosphates; D053583:Interleukin-1beta; D043783:Receptor, Bradykinin B1; D013449:Sulfonamides; D016211:Transforming Growth Factor alpha; D007609:Kallidin; C052787:kallidin, des-Arg(10)-; C065679:icatibant; D009952:Ornithine; D015232:Dinoprostone; D001920:Bradykinin